Literature DB >> 32634278

Liver mitochondrial DNA damage and genetic variability of Cytochrome b - a key component of the respirasome - drive the severity of fatty liver disease.

C J Pirola1,2, M Garaycoechea3, D Flichman4, G O Castaño5, S Sookoian1,6.   

Abstract

BACKGROUND AND AIMS: The progression of nonalcoholic fatty liver disease (NAFLD) into severe histological forms (steatohepatitis - NASH) is paralleled by the occurrence of complex molecular processes. Mitochondrial dysfunction is a hallmark feature of advanced disease. Mitochondrially encoded cytochrome B (cytochrome b, MT-CYB), a member of the oxidative phosphorylation system, is a key component of the respirasome supercomplex. Here, we hypothesized that NAFLD severity is associated with liver tissue cytochrome b mutations and damaged mitochondrial DNA (mtDNA).
METHODS: We included 252 liver specimens of NAFLD patients - in whom histological disease ranged from mild to severe - which were linked to clinical and biochemical information. Tissue molecular explorations included MT-CYB sequencing and analysis of differential mtDNA damage. Profiling of circulating Krebs cycle metabolites and global liver transcriptome was performed in a subsample of patients. Tissue levels of 4-hydroxynonenal - a product of lipid peroxidation and 8-hydroxy-2'-deoxyguanosine, a marker of oxidative damage - were measured.
RESULTS: Compared to simple steatosis, NASH is associated with a higher level of MT-CYB variance, 12.1 vs. 15.6 substitutions per 103  bp (P = 5.5e-10). The burden of variants was associated with increased levels of 2-hydroxyglutarate, branched-chain amino acids, and glutamate, and changes in the global liver transcriptome. Liver mtDNA damage was associated with advanced disease and inflammation. NAFLD severity was associated with increased tissue levels of DNA oxidative adducts and lipid peroxyl radicals.
CONCLUSION: NASH is associated with genetic alterations of the liver cellular respirasome, including high cytochrome b variation and mtDNA damage, which may result in broad cellular effects.
© 2020 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  MT-CYB; NASH; fibrosis; genetics; mitochondrial DNA; oxidative damage; transcriptome

Mesh:

Substances:

Year:  2020        PMID: 32634278     DOI: 10.1111/joim.13147

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  12 in total

Review 1.  Environmental Chemical Exposures and Mitochondrial Dysfunction: a Review of Recent Literature.

Authors:  Aalekhya Reddam; Sarah McLarnan; Allison Kupsco
Journal:  Curr Environ Health Rep       Date:  2022-07-28

Review 2.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

3.  Association between mitochondrial DNA haplogroups J and K, serum branched-chain amino acids and lowered capability for endurance exercise.

Authors:  Jukka M Kiiskilä; Ilmo E Hassinen; Johannes Kettunen; Laura Kytövuori; Ilona Mikkola; Pirjo Härkönen; Jari J Jokelainen; Sirkka Keinänen-Kiukaanniemi; Markus Perola; Kari Majamaa
Journal:  BMC Sports Sci Med Rehabil       Date:  2022-05-26

Review 4.  Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk.

Authors:  Siarhei A Dabravolski; Evgeny E Bezsonov; Mirza S Baig; Tatyana V Popkova; Ludmila V Nedosugova; Antonina V Starodubova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 5.  Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.

Authors:  Eirini Martinou; Marinos Pericleous; Irena Stefanova; Vasha Kaur; Angeliki M Angelidi
Journal:  Diagnostics (Basel)       Date:  2022-02-04

6.  Analysis of mitochondrial DNA cytochrome-b (CYB) and ATPase-6 gene mutations in COVID-19 patients.

Authors:  Ebubekir Dirican; Şeyda Tuba Savrun; İsmail Erkan Aydın; Gonca Gülbay; Ülkü Karaman
Journal:  J Med Virol       Date:  2022-03-22       Impact factor: 20.693

Review 7.  Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives.

Authors:  Marcello Dallio; Mario Romeo; Antonietta Gerarda Gravina; Mario Masarone; Tiziana Larussa; Ludovico Abenavoli; Marcello Persico; Carmelina Loguercio; Alessandro Federico
Journal:  Nutrients       Date:  2021-05-15       Impact factor: 5.717

Review 8.  The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease.

Authors:  Cornelius Engelmann; Frank Tacke
Journal:  Int J Mol Sci       Date:  2022-01-07       Impact factor: 5.923

Review 9.  It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?

Authors:  Giovanni Tarantino; Clara Balsano; Silvano Junior Santini; Giovanni Brienza; Irma Clemente; Benedetta Cosimini; Gaia Sinatti
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

Review 10.  Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.

Authors:  Agostino Di Ciaula; Giuseppe Calamita; Harshitha Shanmugam; Mohamad Khalil; Leonilde Bonfrate; David Q-H Wang; Gyorgy Baffy; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-07-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.